Phase 2 N=104 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 4.2; 8.3 months — p=0.36
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=330 Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
Chronic Pain
Primary: Participants With Adverse Experiences — 51; 98; 135; 284 Participants
N/A N=30 Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males
Healthy
Primary: 'Acute-upon-chronic Effect' of Tea vs Control — 8.03; 9.03 percentage of change in diameter — p=0.09
N/A N=124 Measuring Adherence to Control Hypertension
Hypertension
Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001
Phase 2 N=16 GSK2339345 Hypertussive Challenge Study
Cough
Primary: Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A) — 152.7; 192.5 cough count
N/A N=60 AcuSleep in Mild Traumatic Brain Injury (TBI)
Brain Injuries, Traumatic · Sleeplessness
Primary: PSQI Change — -2.38; -4.43 change of points from baseline
N/A N=43 The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
Adult Growth Hormone Deficiency · Hypothalamic-pituitary Disorders
Primary: Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD). — 0.9; 0.6; 0.7 ng/mL
Phase 2 N=36 A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Safety (Number of Participants With Treatment Related Adverse Events) — 4; 1; 2; 2 Participants
Phase 4 N=101 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus
Primary: Liver Histology (Using Kleiner et al Criteria, Hepatology 2005) — 9; 29 Participants
N/A N=41 Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children
Hyperlipidemias
Primary: Total Cholesterol — 166; 178; 167; 169 mg/dL
Phase 2 N=37 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Macular Edema · Diabetes Mellitus
Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units
Phase 2 N=36 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Non-Hodgkin Lymphoma (NHL) · Cutaneous Lymphoma · Cutaneous T-cell Lymphoma (CTCL)
Primary: Overall Response Rate (ORR) — 70; 56; 79; 100 percentage
N/A N=160 Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
Smoking
Primary: Concentration of Monohydroxybutenylmercapturic Acid (MHBMA) — 110.96; 882.25; 94.97 pg/mg creat — p=<0.001
Phase 3 N=49 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans
End Stage Renal Disease · Kidney Transplantation
Primary: Cumulative One-year Acute Rejection Rates — 7 Participants — p=0.28
N/A N=12 Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health
Metabolic Syndrome X
Primary: Blood Triglyceride — 0.9; 0.8; 0.9 mmol/L